Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
At Arcutis Biotherapeutics, Inc., former officer Larry Todd Edwards reported a proposed sale of 60,376 common shares through Merrill Lynch, with an aggregate market value of $1,992,408 and an approximate sale date of October 20, 2026. The notice also lists sales during the prior three months: 4,730 shares for $123,834.71 on August 17, 2026, and 50,292 shares for $1,257,300 plus 291,688 shares for $8,298,524 on September 16, 2026.
Arcutis Biotherapeutics, Inc. director Howard G. Welgus exercised fully vested stock options for 4,094 common shares and sold 4,728 shares on October 15, 2026, at $26.93 per share. The transactions were effected under a 10b5-1 trading plan adopted March 13, 2026, with a plan end date of June 15, 2027.
Arcutis Biotherapeutics, Inc. (ARQT) director Howard Welgus reported a proposed sale of 4,728 common shares, with an aggregate market value of $127,325.04. Merrill Lynch is listed as the broker, NASDAQ as the exchange, and October 15, 2026, as the approximate sale date.
Welgus also reported earlier sales of 4,730 shares on August 17, 2026, for $123,834.71, and 4,730 shares on September 15, 2026, for $114,371.40.
Arcutis Biotherapeutics, Inc. (ARQT) is the issuer whose common stock BlackRock, Inc. reported beneficially owning 17,751,435 shares, or 14.1% of the class. BlackRock reported sole voting power over 17,576,492 shares and sole dispositive power over 17,751,435 shares, with shared voting and dispositive power of 0 shares. The report identifies iShares Core S&P Small-Cap ETF as having an interest in more than 5% of ARQT’s outstanding common stock. Spencer Fleming, Managing Director, signed the amendment.
Arcutis Biotherapeutics, Inc. (ARQT) executive Matsuda Masaru, EVP and Chief Legal Officer, reported selling 3,674 shares of common stock on September 16, 2026 in an open market or private transaction at a weighted average price of about $25.00 per share, with prices ranging from $25.00 to $25.01. Following this sale, he directly holds 112,508 shares of Arcutis common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026, which has a plan end date of September 1, 2027.
Arcutis Biotherapeutics, Inc. director Howard G. Welgus reported multiple option exercises and a share sale in Arcutis (ARQT) on September 15, 2026. He exercised stock options to acquire an aggregate 4,096 shares of common stock at exercise prices of $6.5223, $7.51, and $8.63 per share, all from fully vested options. On the same date, he sold 4,730 shares of common stock at $24.18 per share in an open-market or private transaction. All reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027.
Arcutis Biotherapeutics, Inc. (ARQT) is the issuer for which former officer Larry Todd Edwards filed a Form 144 notice of proposed sale of restricted or control securities. The notice covers up to 341,980 shares of Arcutis common stock, with an aggregate market value of $8,549,500, to be sold through Merrill Lynch on or after September 16, 2026.
The shares relate to stock option exercises dated September 27, 2023 (170,000 shares), January 12, 2024 (113,667 shares), February 28, 2025 (50,292 shares), and February 27, 2026 (8,021 shares), all for cash. Arcutis common shares outstanding were 125,691,961 as of this notice; this is a baseline figure, not the amount being offered.
Arcutis Biotherapeutics, Inc. (ARQT) is the issuer for which director Howard Welgus has filed a notice of proposed sales under Rule 144. The filing covers the planned sale of 4,730 shares of common stock, with an aggregate market value of $114,371.40, through a brokerage firm on NASDAQ.
Arcutis Biotherapeutics, Inc. (ARQT) reported that EVP and Chief Legal Officer Masaru Matsuda sold 9,989 shares of common stock on September 8, 2026 in an open‑market or private transaction at a weighted average price of $25.03 per share, with individual trade prices ranging from $25.00 to $25.12. Following this sale, he directly holds 116,182 shares of Arcutis common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026, with a plan end date of September 1, 2027.
Arcutis Biotherapeutics, Inc. (ARQT) received a notice under Rule 144 that officer Masaru Matsuda plans to sell 13,663 shares of common stock through broker Merrill Lynch on or about September 8, 2026. The filing lists an aggregate market value of $341,933 for these planned sales and notes that 125,691,961 shares of common stock are outstanding. The shares derive from multiple restricted stock vesting events between May 2024 and August 2025, and the filing also reports a prior sale of 1,230 shares for $32,123.66 on August 3, 2026.